Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video

By: Newsfile
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently granted permission to conduct a Phase 1 clinical study of DMT for the treatment of stroke.



If you cannot view the video above, please visit:
https://www.b-tv.com/post/cse-agn-algernon-pharmaceuticals-advancing-dmt-into-a-phase-1-clinical-trial-btv-ceo-clips-60sec

Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF)

https://algernonpharmaceuticals.com/

About CEO Clips:

CEO Clips – are short company video profiles broadcast to a large audience of investors on TV and 15+ financial sites including Reuters, Yahoo!Finance, and Wall Street Journal.

BTV – Business Television/CEO Clips

Discover Companies to Invest in

www.b-tv.com

Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/143122

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  257.75
-8.91 (-3.34%)
AAPL  352.78
-3.49 (-0.98%)
AMD  504.28
-29.78 (-5.58%)
BAC  50.08
-0.94 (-1.84%)
GOOG  281.26
-11.26 (-3.85%)
META  626.41
-15.28 (-2.38%)
MSFT  517.99
-5.89 (-1.12%)
NVDA  156.14
-6.71 (-4.12%)
ORCL  119.09
-6.26 (-4.99%)
TSLA  379.74
-10.48 (-2.69%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.